Tirzepatide Dosage Chart: How Filipinos Should Titrate from 2.5 mg to 15 mg
Key takeaways
- The the manufacturer-approved schedule for branded the branded tirzepatide pen and weight-management tirzepatide:
- The most common pattern: nausea, GI symptoms, and fatigue spike in the first 4 to 7 days after each step-up, then improve.
- Branded branded tirzepatide products come in pre-measured pens.
- Three common reconstitution concentrations and the volumes needed at each:
- The dosing math assumes the vial contains the labelled tirzepatide at the labelled mass.
Tirzepatide is dosed weekly, titrated upward in 2.5 mg increments every 4 weeks, with the maximum approved dose at 15 mg. The titration schedule on the manufacturer prescribing information is the same internationally and is the schedule Filipino weight-management clinics follow. The complications come from compounded tirzepatide vials, where the concentration is not standardised, the dosing math is on the patient, and the label may not match what is in the vial.
This guide is a practical dose-chart article. We cover the standard 24-week titration schedule for branded branded tirzepatide products, what to do at each step if side effects are intolerable, the dosing math for compounded tirzepatide vials in units (the question Filipino grey-market buyers ask most often), and the verification step that closes the loop on whether your vial actually contains what the label says.
For the broader pillar context on tirzepatide as a molecule, see our Tirzepatide Philippines complete guide. For the practical injection technique, see how to inject tirzepatide safely. For side-effect management at each titration step, see tirzepatide side effects.
The standard titration chart
The the manufacturer-approved schedule for branded the branded tirzepatide pen and weight-management tirzepatide:
| Week range | Weekly dose | Pen strength (branded pen / weight-management tirzepatide) | Notes |
|---|---|---|---|
| Weeks 1 to 4 | 2.5 mg | 2.5 mg pen | Starter dose. Not therapeutic; tolerance-building. |
| Weeks 5 to 8 | 5 mg | 5 mg pen | First therapeutic dose. |
| Weeks 9 to 12 | 7.5 mg | 7.5 mg pen | Mid-dose. Many patients see meaningful weight loss here. |
| Weeks 13 to 16 | 10 mg | 10 mg pen | Approaching higher-dose efficacy. |
| Weeks 17 to 20 | 12.5 mg | 12.5 mg pen | Step before maximum. |
| Weeks 21 to 24 onward | 15 mg | 15 mg pen | Maximum approved dose. Maintenance. |
The schedule is conservative for a reason. Tirzepatide produces strong gastrointestinal side effects at higher doses, and the body adapts to each dose level over the 4-week interval. Skipping steps or escalating faster than 4-week intervals raises side-effect intensity without improving long-term outcomes.
Some patients reach therapeutic effect at 5 mg or 7.5 mg and stay there indefinitely. Some need the full 15 mg for sustained weight-loss progression. There is no clinical penalty for stopping titration at a tolerated effective dose.
What to do at each step if side effects are intolerable
The most common pattern: nausea, GI symptoms, and fatigue spike in the first 4 to 7 days after each step-up, then improve. If the side effects do not improve or are severely intolerable:
Option 1: Stay at the current dose for an additional 4 weeks. Allow more adaptation time before stepping up. This is the most common adjustment and does not represent treatment failure.
Option 2: Drop back to the previous tolerated dose. Stay there for 4 weeks. Then attempt the step-up again. Some patients need two attempts at a step.
Option 3: Add anti-emetic support. Ondansetron 4 to 8 mg or metoclopramide as prescribed by your physician, taken before or after meals during the first week of a step-up.
Option 4: Stop the step-up entirely. If you are at 7.5 mg or 10 mg and tolerating with adequate weight-loss progression, you do not need to escalate further. Many Filipino patients maintain at sub-maximal doses long-term.
When to stop the drug rather than step back: severe persistent vomiting causing dehydration, signs of pancreatitis (severe upper abdominal pain), or signs of biliary obstruction (right upper quadrant pain with fever or jaundice). These are emergencies, not titration adjustments.
Compounded tirzepatide: the dosing math gets harder
Branded branded tirzepatide products come in pre-measured pens. The patient dials the dose; the pen delivers it. There is no math.
Compounded tirzepatide vials, sold by US compounding pharmacies and increasingly by grey-market sellers in the Philippines, are different. The vial contains tirzepatide reconstituted in bacteriostatic water at a specific concentration. The patient draws a measured volume into a syringe and injects.
The dosing math depends on:
- Total tirzepatide in the vial (label claim, often 10 mg, 20 mg, 30 mg, or 60 mg).
- Volume of bacteriostatic water added at reconstitution (typically 1 mL or 2 mL).
- Resulting concentration in mg per mL.
- Syringe volume needed to deliver the target weekly dose.
A worked example. A 30 mg vial reconstituted with 1.5 mL of bacteriostatic water:
- Concentration: 30 mg / 1.5 mL = 20 mg/mL.
- For a 2.5 mg dose: 2.5 / 20 = 0.125 mL.
- For a 5 mg dose: 5 / 20 = 0.25 mL.
- For a 10 mg dose: 10 / 20 = 0.5 mL.
In insulin syringe units (where 1 mL = 100 units):
- 2.5 mg dose at 20 mg/mL: 12.5 units.
- 5 mg dose at 20 mg/mL: 25 units.
- 10 mg dose at 20 mg/mL: 50 units.
- 15 mg dose at 20 mg/mL: 75 units.
The conversion is straightforward only if the vial actually contains the labelled tirzepatide at the labelled mass. If the vial is underdosed (50% of label), the patient drawing 25 units at 20 mg/mL is actually delivering 2.5 mg of tirzepatide, not 5 mg. Weight-loss progress will be slower than expected. This is the central authentication problem with compounded tirzepatide.
For the practical injection technique with compounded vials, see how to inject tirzepatide safely.
Compounded tirzepatide dosing chart at common concentrations
Three common reconstitution concentrations and the volumes needed at each:
At 5 mg/mL (a 10 mg vial reconstituted with 2 mL):
| Dose | Volume | Insulin syringe units |
|---|---|---|
| 2.5 mg | 0.5 mL | 50 |
| 5 mg | 1 mL | 100 |
| 7.5 mg | 1.5 mL | 150 |
| 10 mg | 2 mL | 200 |
(Note: 10 mg from a 10 mg vial uses the entire vial in one dose; less practical for fractional dosing.)
At 10 mg/mL (a 20 mg vial reconstituted with 2 mL):
| Dose | Volume | Insulin syringe units |
|---|---|---|
| 2.5 mg | 0.25 mL | 25 |
| 5 mg | 0.5 mL | 50 |
| 7.5 mg | 0.75 mL | 75 |
| 10 mg | 1 mL | 100 |
| 15 mg | 1.5 mL | 150 |
At 20 mg/mL (a 30 mg vial reconstituted with 1.5 mL, or a 60 mg vial with 3 mL):
| Dose | Volume | Insulin syringe units |
|---|---|---|
| 2.5 mg | 0.125 mL | 12.5 |
| 5 mg | 0.25 mL | 25 |
| 7.5 mg | 0.375 mL | 37.5 |
| 10 mg | 0.5 mL | 50 |
| 12.5 mg | 0.625 mL | 62.5 |
| 15 mg | 0.75 mL | 75 |
Higher concentrations make small dose volumes harder to measure precisely. A 12.5-unit reading on an insulin syringe is harder to hit than a 25-unit reading. Filipino users running compounded tirzepatide should choose reconstitution volumes that put the typical dose in the 25 to 75 unit range for measurement accuracy.
Why concentration accuracy matters more than the math
The dosing math assumes the vial contains the labelled tirzepatide at the labelled mass. The math itself is straightforward arithmetic. The problem is the assumption.
Independent laboratory analysis of compounded and grey-market tirzepatide vials, including by an established international peptide-testing laboratory (Czechia), another international laboratory (USA), and various Southeast Asian regulatory agencies, has documented:
- Underdosed vials at 30 to 70% of labelled tirzepatide content.
- Wrong-API vials containing semaglutide instead of tirzepatide. Semaglutide is cheaper to source.
- No-API vials containing only bacteriostatic water or saline.
- Authentic tirzepatide contaminated with high endotoxin or microbial loads.
A patient running the dosing math correctly on a 50%-underdosed vial is delivering 50% of the intended dose. Weight-loss progression looks like the patient is on a sub-therapeutic dose, because pharmacologically the patient is on a sub-therapeutic dose. The math is right; the vial is wrong.
For the visual authentication of branded product (which compounded vials cannot use because they are not branded), see how to spot fake tirzepatide and branded semaglutide. Visual checks on a compounded vial are limited; the only objective verification is analytical chemistry.
Verifying your tirzepatide vial
Lumen Labs runs the analytical pathway that closes the loop:
- HPLC purity at the tirzepatide absorbance wavelength.
- LC-MS identity against the published tirzepatide mass (4813.5 Da). Catches semaglutide substitution: semaglutide mass is 4113.6 Da, easily distinguishable.
- Quantitation in milligrams per millilitre against the labelled dose.
- Optional endotoxin (LAL) and microbial limits (USP 61) for the contamination question.
The output is a certificate of analysis showing measured tirzepatide concentration with uncertainty range. The Filipino user comparing the COA-measured concentration to the label can recalculate the actual dose being delivered, or can decide to source a different vial with verified concentration.
For grey-market and compounded tirzepatide users in the Philippines, the verification step is the difference between titrating to a known dose and titrating blind. The cost of one Lumen Labs test is small relative to running an underdosed vial for 12 weeks and concluding the drug "does not work".
Storage and shelf-life considerations affecting dose
Tirzepatide is a peptide and degrades over time, faster at higher temperatures. Filipino users should be aware:
- Branded branded tirzepatide / weight-management tirzepatide pens: refrigerated 2 to 8 degrees Celsius. After first use, can be kept at room temperature up to 30 degrees for a limited window per the manufacturer's prescribing information.
- Compounded vials: refrigerated. Once reconstituted, typically used within 4 to 6 weeks; some compounded vials are designed for longer storage but check the supplier specification.
- Repeated freeze-thaw: degrades peptides. Avoid.
- Direct sunlight or heat: degrades peptides. Store in a dark cool location.
A vial that has been stored improperly may have reduced active concentration even if it tested at the correct concentration when fresh. Storage history matters and is worth tracking.
Bottom line on tirzepatide dosing for Filipinos
The branded branded tirzepatide products titration schedule is straightforward: 2.5 mg for 4 weeks, then 5, 7.5, 10, 12.5, 15 mg in 4-week intervals. Patients adjust pace based on tolerance and weight-loss progression. Many patients maintain at sub-maximum doses indefinitely.
Compounded tirzepatide adds the dosing math and the authentication question. The math is straightforward arithmetic if the vial contains what the label says. The authentication is solved by analytical chemistry, not visual inspection or vendor-supplied COAs.
Filipino users on branded product can follow the dose chart with confidence in the dose delivered. Filipino users on compounded vials should run the math correctly and verify the vial concentration through independent third-party laboratory analysis at least once per supplier and ideally per batch.
Disclaimer: Lumen Labs provides chemical analysis of submitted samples for harm-reduction and quality-verification purposes. We are not a substitute for medical care. Tirzepatide is a prescription medication; consult a qualified Philippine licensed physician before starting, adjusting, or stopping any therapy.